相关实验视频

Updated: Jan 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

个性化结直肠癌治疗:使用患者衍生的瘤细胞集群进行化疗药物测试

Xiaoyuan Qiu¹, Ruiqiang Li², Jiaolin Zhou¹

¹Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuai Fu Yuan, Dong Cheng District, Beijing 100730, China.

Translational oncology

|September 14, 2025

概括

来自患者的瘤样细胞集群 (PTC) 模型对预测结直肠癌 (CRC) 化疗反应显示出希望. 这些模型提供快速的药物查,帮助CRC患者个性化治疗决策.

科学领域:

在瘤学瘤学.
翻译医学是一种翻译医学.
癌症治疗方法癌症治疗方法

背景情况:

大肠直肠癌 (CRC) 呈现出显著的异质性,需要化学疗法反应的预测模型.
个性化治疗策略需要可靠的方法来预测个体患者对化疗的反应.

研究的目的:

开发患者衍生的瘤样细胞群 (PTC) 模型,用于体外药物敏感性查.
为了促进大肠直肠癌 (CRC) 患者个性化化疗选择.

主要方法:

从140个结直肠癌 (CRC) 组织中建立了PTC模型,成功率为88.6%.
在PTC模型中评估化疗药物敏感性,平均在11天内获得结果.
相关联的体外药物敏感性数据与患者的临床结果和随访数据.

主要成果:

PTC模型显示了药物反应的变化,确定了对非标准治疗方案的潜在敏感性.
培养和药物敏感性测试是有效的,平均培养时间约为3天,中位数结果时间为11天.
根据PTC模型预测和实际临床治疗反应之间的一致性,没有观察到无疾病生存率 (DFS) 的显著差异.

结论:

PTC模型提供了高的成功率和快速查,以检测结直肠癌 (CRC) 中的化疗药物敏感性.
这种方法为个性化化疗敏感性查提供了一个有希望的工具.
进一步的临床验证可能使PTC模型能够指导CRC患者的临床治疗决策.

关键词:

辅助性化疗是一种辅助性化疗.结肠直肠癌是一种癌症.药物敏感性测试是药物敏感性测试.患者获得的瘤类似于细胞群.

更多相关视频

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...